

**November 11, 2024**

National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai-400051

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

**Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**  
**(ii) SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

**Sub: Investors Presentation- Quarter II and Half year ended on September 30, 2024 of F.Y. 2024-25 – Orchid Pharma Limited (“the Company”)**

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30, Sub- Para 15 of Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and in continuation to our earlier intimation, dated November 06, 2024, regarding the Analysts/Investors Earning Call scheduled to be held on November 11, 2024 at 04:30 P.M. (IST), please find enclosed the Investors Presentation, inter-alia, including the financial performance of the Company for the Quarter-II and Half year ended on September 30, 2024 of Financial Year 2024-25.

The Investor Presentation is also made available on the website of the Company at [www.orchidpharma.com](http://www.orchidpharma.com).

You are requested to take the above intimation on record.

Thanking You,  
For **Orchid Pharma Limited**

**Kapil Dayya**  
**Company Secretary & Compliance Officer**

***Encl. as above***

# Orchid Pharma Limited

## Financials Q2 & FY 2024-25

- All results in Standalone basis.
- These are approx. nos. for exact nos. pls refer financials.

# Financial Highlights

QTR-2

6M-25



**Top line**

12%

22%

**EBIDTA**

20%

44%

**PBT**

26%

76%

**PAT**

26%


76%

# Financial Performance Summary




(Rs/Crore)	Q2-2025	Q2-2024	Change %	6M-2025	6M-2024	Change %	12M-31 <sup>st</sup> Mar'24
<b>Sales</b>	222.7	198.8	+12%	467.1	381.7	+22%	819.4
<b>Other Income</b>	8.0	7.5		15.7	8.8		30.4
<b>COGS</b>	131.2	122.4		281.4	234.4		484.6
<b>Employee Exp</b>	20.7	17.2		42.0	33.4		69.6
<b>Other Exp</b>	41.3	35.5		80.8	68.0		154.6
<b>EBITDA</b>	37.5	31.2	+20%	78.6	54.7	+44%	141.0
<b>% to Sales</b>	17%	16%		17%	14%		17%
<b>Non Op- Income</b>	0.0	0.7		0.0	1.3		
<b>Interest</b>	3.3	3.8	-13%	6.8	9.3	-27%	16.3
<b>Depreciation</b>	8.6	7.8	+10%	17.1	15.6	+10%	33.2
<b>PBT</b>	25.6	20.3		54.7	31.0		91.5
<b>PAT</b>	25.6	20.3		54.7	31.0		94.7

# Turnover (In Cr.)




# EBIDTA, PBT & PAT as % to Sales Q2-25




# P&L Analysis – Gross Margin % to Sales

Gross Margin Quarterly Basis



# P&L Analysis – Exp. % to Sales Q2-25





**Thank You**